Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Her-2 Negative Breast Cancer × fluzoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 9 Breast Neoplasms 4 Sarcoma 3 Prostatic Neoplasms 3 Neoplasm Metastasis 2 Fallopian Tube Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Sarcoma, Ewing 1 Recurrence 1 Platinum-sensitive Relapsed Ovarian Cancer 1 Osteosarcoma 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Metastatic Castration Resistant Prostate Cancer 1 Kenny-Caffey syndrome, Type 1 1 Her-2 Negative Breast Cancer 1 Female Breast Cancer Patients 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1 Advanced Solid Tumors 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

fluzoparib 1 camrelizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05761470 2023-03-09

IMPARP

First Affiliated Hospital, Sun Yat-Sen University

Phase 2 Recruiting

Her-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡